ImmunoPrecise Antibodies Revenue 2022-2024 | IPA

ImmunoPrecise Antibodies revenue from 2022 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.

ImmunoPrecise Antibodies Revenue 2022-2024 | IPA

ImmunoPrecise Antibodies revenue from 2022 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Related Stocks
Company NameMarket
Cap
GE HealthCare Technologies (GEHC)$40.4B
Tempus AI (TEM)$7.9B
Inspire Medical Systems (INSP)$6.2B
Axonics (AXNX)$3.5B
Hims & Hers Health (HIMS)$3.5B
10x Genomics (TXG)$2.7B
Enovis (ENOV)$2.4B
Azenta (AZTA)$2.4B
Privia Health (PRVA)$2.3B
IRhythm Technologies (IRTC)$2.2B
Omnicell (OMCL)$2B
Clover Health Investments (CLOV)$1.5B
Schrodinger (SDGR)$1.4B
Phreesia (PHR)$1.4B
Standard BioTools (LAB)$753M
Fulgent Genetics (FLGT)$694M
Definitive Healthcare (DH)$538M
Health Catalyst (HCAT)$529M
Butterfly Network (BFLY)$406M
Talkspace (TALK)$343M
Pulmonx (LUNG)$329M
SOPHiA GENETICS SA (SOPH)$286M
TruBridge (TBRG)$183M
P3 Health Partners (PIII)$165M
American Well (AMWL)$147M
Augmedix (AUGX)$115M
EUDA Health Holdings (EUDA)$90M
Future Health ESG (FHLT)$65M
SHL Telemedicine (SHLT)$55M
HeartBeam (BEAT)$53M